Study guide
11.5 Product Indications, Contraindications, and Selection
Wound Care Certified WCC
Track your progress as you read
Finished sections get a check mark.
1 Orientation: NAWCO WCC Exam, Eligibility, and Scoring
1.1 Credential Purpose, Sponsor, and Scope 1.2 Qualifying License and Eligibility Frame 1.3 Education and Experience Pathways 1.4 Exam Format, Delivery, and Timing 1.5 Scoring, Standard Setting, and Confidentiality 1.6 Fees, Scheduling, Retesting, and Recertification
2 Wound Assessment: Etiology, Status, and Skin Integrity
2.1 Assessment Domain and Exam Approach 2.2 Etiology Patterns and Location Clues 2.3 Wound Status: Measurement, Tissue, and Exudate 2.4 Depth, Tissue Loss, and Pressure Injury Language 2.5 Skin Structure, Function, and Barrier 2.6 Skin Integrity Across the Lifespan
3 Patient Assessment: Labs, Nutrition, Pain, and Risk Tools
3.1 Labs and Diagnostic Data in Wound Assessment 3.2 Nutrition, Hydration, and Healing Risk 3.3 Comorbidities, Medications, and Current Condition 3.4 Psychosocial History, Adherence Barriers, and Access 3.5 Pain Assessment Tools and Treatment Tolerance 3.6 Risk Tools, Cognition, Function, and ADLs
4 Treatment Foundations, Dressings, and Wound Bed Preparation
4.1 Cleansing, Wound Hygiene, and Assessment Before Treatment 4.2 Moisture Balance and Core Dressing Functions 4.3 Dressing Categories, Formulary, and Resource Fit 4.4 Periwound Protection, Exudate, and Securement 4.5 Wound Bed Preparation and Debridement Concepts 4.6 Infection Signs, Prevention, and Escalation
5 Advanced Therapies, Diagnostics, Support Surfaces, and Referrals
5.1 Negative Pressure Wound Therapy Readiness and Monitoring 5.2 Electrical Stimulation, Ultrasound, and Topical Adjuncts 5.3 Diagnostics, Cultures, Labs, and Referral Triggers 5.4 Support Surfaces, Pressure Redistribution, and Microclimate 5.5 Offloading, Compression, and Lymphedema Decision-Making 5.6 Hyperbaric Oxygen and Specialty Referral Coordination
6 Infection, Vascular, Diabetic, and Pressure Injury Scenarios
6.1 Local, Spreading, and Systemic Infection Signals 6.2 Biofilm, Colonization, Culture, and Antimicrobial Traps 6.3 Diabetic Foot Ulcer Scenarios: Neuropathy, Perfusion, and Offloading 6.4 Venous, Arterial, and Mixed Vascular Wound Scenarios 6.5 Pressure Injury Prevention, Staging, and Treatment Scenarios 6.6 Integrated Contraindication and Priority Scenarios
7 Reevaluation, Healing Progression, and Treatment Adjustment
7.1 Re-Evaluation Domain and Decision Cycle 7.2 Treatment Choice and Plan Effectiveness 7.3 Weekly Measurement and Trend Monitoring 7.4 Tolerance, Pain, and Treatment Reactions 7.5 Adherence Barriers and Plan Adjustment 7.6 Healing Phases and Progression Decisions
8 Education, Health Literacy, and Interprofessional Teaching
8.1 Education Domain Scope and Priorities 8.2 Patient and Family Treatment-Plan Teaching 8.3 Health Literacy, Plain Language, and Teach-Back 8.4 Language, Cognition, Sensory Needs, and Cultural Adaptation 8.5 Discharge Teaching and Home Adherence 8.6 Interprofessional Team Teaching and Prevention Reinforcement
9 Administration, Protocols, Data Quality, and Care Coordination
9.1 Administration Domain Map for WCC Candidates 9.2 Evidence-Based Protocols and Facility Processes 9.3 Formularies, Product Access, and Treatment-Plan Workflow 9.4 Educational Media and Team Communication Tools 9.5 Data Quality, Prevalence, Incidence, and Outcome Monitoring 9.6 Payers, Case Management, and Transition Coordination
10 Legal Documentation, Ethics, Scope, and Patient Autonomy
10.1 Legal Domain Map for WCC Candidates 10.2 Objective Wound-Characteristic Documentation 10.3 Treatment-Plan Documentation and Continuity 10.4 Scope of Practice, Regulatory Issues, and Consultation 10.5 Ethics, Culture, Palliative Care, and Patient Autonomy 10.6 Confidentiality, Record Integrity, and Exam Conduct
11 Risk, Prevention, At-Risk Populations, and Product Selection
11.1 Risk Framework for Impaired Skin Integrity 11.2 Pressure Prevention, Repositioning, and Support Surfaces 11.3 Moisture, Incontinence, and Periwound Protection 11.4 Offloading, Foot Risk, and At-Risk Populations 11.5 Product Indications, Contraindications, and Selection 11.6 Population-Specific Prevention Across Settings
12 Integrated WCC Case Scenarios and Final Review
12.1 Blueprint-Weighted Final Review Strategy 12.2 Integrated Pressure Injury Case Review 12.3 Integrated Diabetic Foot and Vascular Case Review 12.4 Integrated Venous Leg Ulcer and Compression Case Review 12.5 Legal, Education, and Administration Integrated Cases 12.6 Exam Day, Scoring, Retake, and Recertification Review
11.5 Product Indications, Contraindications, and Selection
Key Takeaways Explain This Topic AI
Product selection follows assessment: etiology, tissue type, drainage level, infection concern, periwound condition, pain, tolerance, and setting.
Contraindication recognition is a core Risk and Prevention task; the wrong product on the wrong wound is a frequent stem.
Match the category function (moisture donation vs. absorption vs. antimicrobial vs. protection), not a brand name.
Traps include moisture-retentive products on unmanaged heavy drainage and aggressive therapies when perfusion or scope is unresolved.
Last updated: June 2026
Product Selection by Indication and Safety
The WCC exam does not require memorizing manufacturer catalogs; it requires knowing why a category is selected and when it is a poor fit. Product choice follows assessment: etiology, tissue type, drainage amount, infection signs, periwound condition, pain, allergies, wear time, setting, cost awareness, and patient/caregiver ability. The blueprint places indications and contraindications squarely in Risk and Prevention, so safety is central.
The guiding principle of moist wound healing is to keep the wound bed moist but the periwound dry. Translate that into a moisture-balance decision: donate moisture to dry wounds (if perfusion and etiology allow) and absorb moisture from heavily draining wounds while protecting the periwound. No dressing compensates for unrelieved pressure, uncontrolled edema, ischemia, or unmanaged diabetes.
Category Map for Exam Reasoning
Category Main function Best for Watch for / contraindication
Transparent film Protect, allow visualization, retain moisture Superficial wounds, IV sites, autolytic adjunct Not for heavy drainage; risk of skin tear on fragile skin
Hydrogel Donates moisture, rehydrates Dry wounds, eschar (autolytic debridement) Macerates if drainage is moderate-heavy
Hydrocolloid Occlusive, supports moist healing, autolytic Light-to-moderate drainage, partial-thickness Avoid with infection or heavy exudate; can macerate
Foam Absorbs light-moderate exudate, cushions Moderate drainage, periwound protection Not a substitute for offloading or turning
Alginate / gelling fiber Absorbs moderate-heavy exudate, may aid hemostasis Heavy drainage, sinus/cavity filling Dries out a low-drainage wound; needs moisture to gel
Barrier film / cream Protects periwound and at-risk skin Periwound, IAD prevention Do not place in the wound bed unless intended
Antimicrobial (silver, iodine, PHMB) Reduces bioburden Critically colonized/infected wounds Reassess need; avoid routine prophylactic use; iodine cautions
Worked Scenarios
A venous-type leg ulcer with moderate drainage and a macerated periwound calls for exudate control (alginate or foam), periwound barrier film, an edema/compression plan only when arterial disease is excluded and compression is ordered , and reassessment of wear time. Add absent pulses or ischemic rest pain to the same stem and the answer shifts to vascular evaluation before compression.
A dry, stable eschar on an ischemic limb is a classic contraindication item: do not apply a moisture-donating hydrogel to soften it, because autolytic debridement of a poorly perfused, noninfected eschar can convert a stable wound into an open, infected one. Keep it dry and refer for perfusion assessment.
Reading Contraindication Clues
Contraindications hide in one or two words: adhesive allergy, fragile/skin-tear-prone skin, heavy drainage, undermining or tunneling, dry eschar on an ischemic limb, exposed bone/tendon, infection signs, or uncontrolled pain can make a familiar product unsafe or incomplete. Slow down when the stem includes perfusion, infection, or scope clues. If the product requires a skill or order outside the WCC role, the correct action is collaboration or referral.
Common Traps and the Administration Angle
Do not pick a product because it sounds advanced; a costly antimicrobial is wrong if the wound simply needs offloading and moisture balance.
Conversely, a plain dressing is inadequate when the stem shows spreading erythema, fever, or malodor with systemic signs.
Real selection respects formularies, payer rules, and home feasibility (hand function, vision, supplies, caregiver support). Prevention fails when a technically correct product is impossible to use. Close the loop by reassessing wound size, tissue, drainage, odor, periwound, pain, and adherence; if the wound stalls, re-examine etiology rather than stacking products.
Matching Absorbency to Drainage Level
A reliable way to answer selection items is to grade exudate and then pick a category with the matching capacity. None to minimal drainage with a dry bed favors a moisture donor (hydrogel) or a simple film. Light drainage suits a hydrocolloid or thin foam. Moderate drainage suits foam. Heavy drainage suits an alginate or gelling-fiber dressing, often with a secondary absorptive cover and a longer reach toward containment for very high output. A mismatch is the classic wrong answer: an alginate on a dry wound desiccates the bed, while a film over a heavily draining wound leaks, macerates, and lifts.
Always re-grade drainage at each change because exudate falls as a wound improves, and the dressing should de-escalate with it.
Adjunctive and Advanced Therapies
The exam may mention negative pressure wound therapy (NPWT) , used to manage exudate and promote granulation in selected deep or heavily draining wounds, but contraindicated over untreated osteomyelitis, malignancy in the wound, exposed unprotected vessels or organs, and necrotic tissue with eschar. Collagen, growth-factor, and cellular/tissue-based products are reserved for clean, adequately perfused, non-healing wounds after standard care has been optimized, not as first-line prevention. Compression is therapy for venous disease only after arterial insufficiency is excluded.
The recurring lesson is that advanced therapy never substitutes for fixing the underlying cause and confirming perfusion.
Allergy, Cost, and Documentation
Screen for adhesive, latex, silver, and iodine sensitivities before selecting a product, and substitute within the same functional category when an allergy is present. Cost and formulary realities matter, but they break ties between equally appropriate products; they never justify an unsafe or mismatched choice. Document the etiology, the wound and periwound assessment, the product category and rationale, contraindications considered, patient tolerance and teaching, and the reassessment date so the selection survives audit and handoff.